Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Anetumab ravtansine (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARCS-Multi
- Sponsors Bayer
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2018 Planned End Date changed from 11 Feb 2020 to 29 Jan 2021.
- 23 May 2018 Planned primary completion date changed from 31 May 2019 to 28 Feb 2020.